ADMA BIOLOGICS INC (ADMA)
US0008991046 - Common Stock
ADMA gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ADMA has only an average score on both its financial health and profitability. ADMA has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ADMA has reported negative net income.
ADMA had a positive operating cash flow in the past year.
In the past 5 years ADMA always reported negative net income.
ADMA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ADMA (-8.58%) is better than 89.73% of its industry peers.
ADMA has a better Return On Equity (-20.88%) than 87.16% of its industry peers.
The Return On Invested Capital of ADMA (6.12%) is better than 96.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.58% | ||
| ROE | -20.88% | ||
| ROIC | 6.12% |
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADMA has a Operating Margin of 8.38%. This is amongst the best in the industry. ADMA outperforms 95.21% of its industry peers.
ADMA has a better Gross Margin (34.44%) than 78.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | N/A | ||
| GM | 34.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ADMA is destroying value.
ADMA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADMA has more shares outstanding
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
ADMA has an Altman-Z score of 4.15. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.15, ADMA is in the better half of the industry, outperforming 79.45% of the companies in the same industry.
The Debt to FCF ratio of ADMA is 34.20, which is on the high side as it means it would take ADMA, 34.20 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 34.20, ADMA belongs to the top of the industry, outperforming 93.84% of the companies in the same industry.
ADMA has a Debt/Equity ratio of 0.97. This is a neutral value indicating ADMA is somewhat dependend on debt financing.
ADMA's Debt to Equity ratio of 0.97 is on the low side compared to the rest of the industry. ADMA is outperformed by 77.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | 34.2 | ||
| Altman-Z | 4.15 |
ROIC/WACC0.65
WACC9.43%
2.3 Liquidity
A Current Ratio of 5.16 indicates that ADMA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.16, ADMA is in line with its industry, outperforming 55.65% of the companies in the same industry.
ADMA has a Quick Ratio of 1.69. This is a normal value and indicates that ADMA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ADMA (1.69) is worse than 78.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.16 | ||
| Quick Ratio | 1.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.06% over the past year.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 67.58%.
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 72.31% on average per year.
EPS 1Y (TTM)58.06%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-33.33%
Revenue 1Y (TTM)67.58%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Revenue growth Q2Q47.87%
3.2 Future
The Earnings Per Share is expected to grow by 44.57% on average over the next years. This is a very strong growth
ADMA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.52% yearly.
EPS Next Y333.42%
EPS Next 2Y143.78%
EPS Next 3Y87.85%
EPS Next 5Y44.57%
Revenue Next Year30.19%
Revenue Next 2Y23.3%
Revenue Next 3Y19.01%
Revenue Next 5Y10.52%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ADMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 21.59, which indicates a rather expensive current valuation of ADMA.
96.40% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
ADMA is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.49, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.59 |
4.2 Price Multiples
95.03% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.84% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 391.42 | ||
| EV/EBITDA | 51.68 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADMA's earnings are expected to grow with 87.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y143.78%
EPS Next 3Y87.85%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADMA BIOLOGICS INC
NASDAQ:ADMA (4/26/2024, 7:00:00 PM)
After market: 6.62 +0.07 (+1.07%)6.55
+0.11 (+1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.49B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.59 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.58% | ||
| ROE | -20.88% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 8.38% | ||
| PM (TTM) | N/A | ||
| GM | 34.44% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.97 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.16 | ||
| Quick Ratio | 1.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.06%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y333.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)67.58%
Revenue growth 3Y82.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y